Linked e-resources
Details
Table of Contents
Intro; Dedication; Foreword; Preface; Acknowledgement; Contents; About the Editor; 1: Epidemiology of Lymphatic Filariasis; 1.1 Introduction; 1.2 Filariasis Control Globally and in India; 1.3 Geographical Distribution; 1.4 Transmission Cycle; 1.5 Reservoir of Infection; 1.6 The Vectors; 1.7 Host Factors; 1.8 Environmental Factors; 1.9 Pathogenesis; 1.10 Clinical Features; 1.11 Infection/Disease Surveillance; 1.12 Current Control Strategy of Lymphatic Filariasis; 1.13 Conclusion; References; 2: Lymphatic Filariasis Elimination: Update for Mission Possible; 2.1 Introduction
2.2 National Filaria Control Programme2.3 Organization Set-Up Recommended for NFCP; 2.4 Disease Endemicity; 2.5 Control Measures; 2.6 Genesis of Elimination of Lymphatic Filariasis (ELF); 2.7 National Goal and Strategy for ELF; 2.8 Mass Drug Administration; 2.9 Drug Compliance Assessment; 2.10 Transmission Assessment Survey (TAS); 2.11 Capacity Building; 2.12 Social Mobilization; 2.13 Morbidity Management; 2.14 Future Plan; References; 3: Next Step Lymphatic Filariasis Eradication: Current Status in the Development of a Vaccine Against Lymphatic Filariasis; 3.1 Introduction
3.2 Development of Immunity Against LF3.2.1 Concept of "Endemic Normal" and Natural Immunity to LF; 3.2.2 The Need for Developing a Vaccine Against LF in the Human; 3.3 Developing a Vaccine Against LF; 3.3.1 Early Attempts to Develop a Vaccine Against LF; 3.3.2 Strategies for Selecting the Vaccine Antigens Against LF; 3.3.3 LF Parasites Modulate Host Immune Responses; 3.3.4 Animal Models and Limitations to Developing a Vaccine Against LF; 3.3.5 Screening Filariasis Genome to Identify Vaccine Candidates; 3.3.6 Improving the Vaccine Efficacy
3.4 Future Prospects and Hurdles Before an LF Vaccine Becomes Available for the End Game to Control the Infection3.5 Concluding Remarks; References; 4: Progress in the Treatment and Control of Lymphatic Filariasis; 4.1 Introduction; 4.2 B. malayi Targets; 4.3 Wolbachia; 4.4 Wolbachia as Antifilarial Target; 4.5 Moxidectin; 4.6 Conclusion and Prospects; References; 5: Immunotechnological Advancements in Developing Vaccines for Lymphatic Filariasis; 5.1 Introduction; 5.2 Filarial Vaccines: Possible or Impossible?; 5.3 Challenges; 5.4 Animal Models for Vaccine Studies
5.5 Milestones in LF Vaccination Studies5.5.1 Parasites and Crude Antigens; 5.5.2 Recombinant Filarial Vaccine Candidates; 5.6 Identification Methods for LF Vaccine Targets; 5.7 Different Categories of LF Vaccine Candidates; 5.7.1 Host-Parasite Interface: A Niche for Vaccine Candidates; 5.7.2 Metabolic Enzymes: Antioxidants; 5.8 Infective Stage-Specific Antigens; 5.8.1 Abundant Larval Transcripts (ALT): A Prototype L3 Stage Candidate Antigen; 5.8.2 Modern Approaches for LF Vaccine Development; 5.9 Immunomics: Identification of Immunogenic Proteins; 5.10 Peptide Vaccine Approach
2.2 National Filaria Control Programme2.3 Organization Set-Up Recommended for NFCP; 2.4 Disease Endemicity; 2.5 Control Measures; 2.6 Genesis of Elimination of Lymphatic Filariasis (ELF); 2.7 National Goal and Strategy for ELF; 2.8 Mass Drug Administration; 2.9 Drug Compliance Assessment; 2.10 Transmission Assessment Survey (TAS); 2.11 Capacity Building; 2.12 Social Mobilization; 2.13 Morbidity Management; 2.14 Future Plan; References; 3: Next Step Lymphatic Filariasis Eradication: Current Status in the Development of a Vaccine Against Lymphatic Filariasis; 3.1 Introduction
3.2 Development of Immunity Against LF3.2.1 Concept of "Endemic Normal" and Natural Immunity to LF; 3.2.2 The Need for Developing a Vaccine Against LF in the Human; 3.3 Developing a Vaccine Against LF; 3.3.1 Early Attempts to Develop a Vaccine Against LF; 3.3.2 Strategies for Selecting the Vaccine Antigens Against LF; 3.3.3 LF Parasites Modulate Host Immune Responses; 3.3.4 Animal Models and Limitations to Developing a Vaccine Against LF; 3.3.5 Screening Filariasis Genome to Identify Vaccine Candidates; 3.3.6 Improving the Vaccine Efficacy
3.4 Future Prospects and Hurdles Before an LF Vaccine Becomes Available for the End Game to Control the Infection3.5 Concluding Remarks; References; 4: Progress in the Treatment and Control of Lymphatic Filariasis; 4.1 Introduction; 4.2 B. malayi Targets; 4.3 Wolbachia; 4.4 Wolbachia as Antifilarial Target; 4.5 Moxidectin; 4.6 Conclusion and Prospects; References; 5: Immunotechnological Advancements in Developing Vaccines for Lymphatic Filariasis; 5.1 Introduction; 5.2 Filarial Vaccines: Possible or Impossible?; 5.3 Challenges; 5.4 Animal Models for Vaccine Studies
5.5 Milestones in LF Vaccination Studies5.5.1 Parasites and Crude Antigens; 5.5.2 Recombinant Filarial Vaccine Candidates; 5.6 Identification Methods for LF Vaccine Targets; 5.7 Different Categories of LF Vaccine Candidates; 5.7.1 Host-Parasite Interface: A Niche for Vaccine Candidates; 5.7.2 Metabolic Enzymes: Antioxidants; 5.8 Infective Stage-Specific Antigens; 5.8.1 Abundant Larval Transcripts (ALT): A Prototype L3 Stage Candidate Antigen; 5.8.2 Modern Approaches for LF Vaccine Development; 5.9 Immunomics: Identification of Immunogenic Proteins; 5.10 Peptide Vaccine Approach